Fresenius

Some brighter views

21/06/22 -"We have revised our models and included all figures. We have become more optimistic about Kabi’s profitability (IV drug’s brake to earnings sorted) and allowed for Helios’ higher than anticipated ..."

PDF page sample
Pages
58
Language
English
Published on
21/06/22
Download
You may also be interested by these reports :
13/10/26
Demant reported robust preliminary Q3 sales figures, driven by strong demand for its newly launched hearing aids. The 2026 guidance has been revised ...
09/10/26
Our target price has been revised downwards due to updated estimates following management’s decision to lower the upper end of its topline guidance ...
08/10/26
Our target price has increased due to a higher NAV and DCF, along with a 20% premium applied to our peer-based valuation metrics, excluding dividend ...
08/10/26
The TP increase reflects upgrades to our DCF and NAV (discussed above). The investment case remains compelling: consumables-led growth, the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO